payor coverage

While orders of its Liquid GPS are increasing, Soon-Shiong expressed frustration with the slow pace of reimbursement and urged investor patience.

The San Diego Union-Tribune reports on the difficulties health insurers face with new gene and cell therapies.

Highmark will examine the clinical and economic impact of Biocept's Target Selector liquid biopsy in patients with non-small cell lung cancer.

Slow Coverage

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.

Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.

The Center for Genomic Interpretation and NSGC want payors to cover confirmatory testing for patients with positive results from 23andMe's FDA-cleared test.

CMS will reimburse FoundationOne CDx at a rate of $3,500 per test for a nine-month period starting July 1.

The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.

The coverage decisions follow similar decisions by Blue Shield of California and First Coast Service Options last year.

Pages

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.